13.78 +0.38 (2.84%)
After hours: 6:18PM EDT
|Bid||13.50 x 900|
|Ask||13.80 x 2200|
|Day's Range||12.68 - 13.83|
|52 Week Range||11.30 - 27.50|
|Beta (3Y Monthly)||3.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.43|
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Gilead Sciences’ (GILD) selling, general, and administrative expenses increased from $897.0 million in the second quarter of 2017 to $980.0 million in the second quarter. The increase was due to higher stock-based compensation expenses and costs after the Kite acquisition.
On October 4, Sangamo Therapeutics (SGMO) stock ended the trading day at $14.81—down ~3.4% from the previous day’s close. The stock registered its 52-week high of $27.50 on February 22. Sangamo Therapeutics reported its 52-week low of $11.30 on October 26, 2017. Currently, the stock is trading ~5.5% lower than its 50-day moving average of $15.68 and ~9% lower than its 200-day moving average of $16.27.
Sangamo Therapeutics (SGMO), a clinical stage biotechnology firm, is focused on developing gene-based therapies using industry-leading technology platforms in gene therapy, cell therapy, genome editing, and gene regulation. The company has collaborations with a number of leading pharmaceuticals firms including Gilead Sciences (GILD), Sanofi (SNY), and Pfizer (PFE) to develop a wide range of genomic therapies. In this part, we’ll discuss Sangamo Therapeutics’ recent recommendations and target prices from Wall Street analysts.
RICHMOND, Calif. and VALBONNE, France, Oct. 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) and TxCell S.A. (TXCL.PA) today jointly announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of €2.58 per share in cash, representing approximately 53% of the share capital and voting rights of TxCell, as per the terms of the Share Purchase Agreement entered into on July 20, 2018 (the "SPA") and announced previously by TxCell and Sangamo in a joint press release dated July 23, 2018.
Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.
RICHMOND, Calif. , Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor and industry conferences ...
HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is ...
Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.
Sangamo Therapeutics (SGMO) is focused on developing and commercializing novel genomic therapies. Its genome editing and gene regulation platform is based on the engineering of a type of transcription factors called zinc finger DNA binding proteins (or ZFP) that naturally occur in humans. Sangamo has entered into key collaborations with Kite Pharma, a subsidiary of Gilead Sciences (GILD) and Pfizer (PFE).
Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.
A look at the shareholders of Sangamo Therapeutics Inc (NASDAQ:SGMO) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million compared to $5.9 million in the second quarter of 2017. Intellia Therapeutics’ collaboration agreement with Regeneron Pharmaceuticals (REGN) primarily contributed to the increase in its collaboration revenue in the second quarter. In the first half of 2018, Intellia Therapeutics reported net collaboration revenue of $15.1 million compared to $12.1 million in the first half of 2017.
In the second quarter, CRISPR Therapeutics reported net income and EPS (earnings per share) of -$38.4 million and -$0.82, respectively, compared to net income and EPS of -$22.3 million and -$0.56 in the second quarter of 2017. In the first half of the year, CRISPR Therapeutics reported net income and EPS of -$66.7 million and -$1.44, respectively, compared to -$43.8 million and -$1.10 in the first half of 2017.
CRISPR Therapeutics (CRSP) has already obtained approval for clinical trial applications (or CTA) across multiple countries for its CTX001, an investigational autologous gene-edited hematopoietic stem cell therapy for the treatment of individuals with severe hemoglobinopathies. CRISPR Therapeutics and its partner, Vertex Pharmaceuticals, obtained CTA approvals for the evaluation of the therapy for the treatment of beta-thalassemia and sickle cell disease.
The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body.
Bluebird Bio (BLUE) is a clinical stage biotechnology company. It reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline YoY (year-over-year) compared to $16.72 million in the second quarter of 2017.
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Shares of one stock soared over 120% on positive results from a trial while the other collapsed on its trial results. ProQR was the winner with a gain of over 120% while Sangamo Therapeutics sank nearly 24%. ProQR Therapeutics N.V. shares exploded on Wednesday and closed up 120.75% on high trading volume.